Form 6-K Evogene Ltd. For: Aug 11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2021
Commission File Number 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street
Park Rehovot P.O.B 4173
Ness Ziona 7414003, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of
the Company approved all the Proposals brought before the annual general meeting of shareholders held on August 10, 2021 (following a one-week adjournment from the original meeting date) (the “Meeting”), by
the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company’s Report of Foreign
Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on June 23, 2021 (the “Proxy Statement”), and sent in connection with the
Meeting.
8,470,114 ordinary shares, representing approximately 20.85% of the issued and outstanding ordinary shares as of the record date, were present or represented by proxy at the
Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-253300), and Form
S-8 (SEC File Nos. 333-193788, 333-201443 and 333-203856) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 11, 2021 |
EVOGENE LTD.
(Registrant) By: /s/ Dorit Kreiner —————————————— Dorit Kreiner Chief Financial Officer |
|||
3
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EverGen Infrastructure Reports Q4 & Year End 2023 Results
- Thin Film Material Market Projected to Reach USD 18.99 Billion by 2031 Due to Surging Demand for Efficiency and Miniaturization
- Climate Risk Analytics Company, FLINTpro, Expands Globally with US & UK Hires and New US Headquarters
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!